Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Matthias G. J. Baud"'
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 1, Iss 5, Pp 273-312 (2020)
PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” to bind to a protein of interest, connected by a chemical linker. Targeted prot
Externí odkaz:
https://doaj.org/article/480d570d74fb441795534cac8341c5cc
Autor:
Vitaly Chasov, Regina Mirgayazova, Ekaterina Zmievskaya, Raniya Khadiullina, Aygul Valiullina, Joseph Stephenson Clarke, Albert Rizvanov, Matthias G. J. Baud, Emil Bulatov
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The transcription factor p53 is a key tumor suppressor that is inactivated in almost all cancers due to either point mutations in the TP53 gene or overexpression of its negative regulators. The p53 protein is known as the “cellular gatekeeper” fo
Externí odkaz:
https://doaj.org/article/bd5dac044856409a9eb9ccd1aa8db9b8
Autor:
Raysa Khan, Graham Marsh, Robert Felix, Paul D. Kemmitt, Matthias G. J. Baud, Alessio Ciulli, John Spencer
Publikováno v:
ACS Omega, Vol 2, Iss 8, Pp 4328-4332 (2017)
Externí odkaz:
https://doaj.org/article/7e439ba1cfaf4f858713a7fd575c437d
Autor:
Matthias G. J. Baud, Thomas Leiser, Vanessa Petrucci, Mekala Gunaratnam, Stephen Neidle, Franz-Josef Meyer-Almes, Matthew J. Fuchter
Publikováno v:
Beilstein Journal of Organic Chemistry, Vol 9, Iss 1, Pp 81-88 (2013)
There has been significant interest in the bioactivity of the natural product psammaplin A, most recently as a potent and isoform selective HDAC inhibitor. Here we report our preliminary studies on thioester HDAC inhibitors derived from the active mo
Externí odkaz:
https://doaj.org/article/15c3558b35ce4570b7935c627ab031e1
Autor:
Michael A. McCoy, Dominique Spicer, Neil Wells, Kurt Hoogewijs, Marc Fiedler, Matthias G. J. Baud
Publikováno v:
Journal of Medicinal Chemistry. 65:7246-7261
The canonical Wingless-related integration site signaling pathway plays a critical role in human physiology, and its dysregulation can lead to an array of diseases. β-Catenin is a multifunctional protein within this pathway and an attractive yet cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8de55edcf2e62da4fe43dcd6d30f785a
https://doi.org/10.1021/acs.jmedchem.2c00228
https://doi.org/10.1021/acs.jmedchem.2c00228
Autor:
Joseph R. Stephenson Clarke, Leon R. Douglas, Patrick J. Duriez, Dimitrios-Ilias Balourdas, Andreas C. Joerger, Raniya Khadiullina, Emil Bulatov, Matthias G. J. Baud
Publikováno v:
ACS pharmacologytranslational science. 5(11)
The tumor suppressor protein p53 is inactivated in the majority of human cancers and remains a prime target for developing new drugs to reactivate its tumor suppressing activity for anticancer therapies. The oncogenic p53 mutant Y220C accounts for ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f4c292cd3b44b8d4084ffa7acad8b2f
https://pubmed.ncbi.nlm.nih.gov/36407959
https://pubmed.ncbi.nlm.nih.gov/36407959
Autor:
Regina Mirgayazova, Joseph Richard Stephenson Clarke, Albert A. Rizvanov, V. V. Chasov, Emil Bulatov, Aygul Valiullina, Matthias G. J. Baud, Raniya Khadiullina, Ekaterina Zmievskaya
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology, Vol 10 (2020)
The transcription factor p53 is a key tumor suppressor that is inactivated in almost all cancers due to either point mutations in the TP53 gene or overexpression of its negative regulators. The p53 protein is known as the “cellular gatekeeper” fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2889247a9d76aec2ebf3be4386c6c0f6
https://doi.org/10.3389/fonc.2020.01460
https://doi.org/10.3389/fonc.2020.01460
Autor:
D. Horil Roy, Alan R. Fersht, Matthias G. J. Baud, Andreas C. Joerger, Matthias R. Bauer, Ketan J. Patel, Felix A. Dingler, L. Verduci
Publikováno v:
European Journal of Medicinal Chemistry
Many cancers have the tumor suppressor p53 inactivated by mutation, making reactivation of mutant p53 with small molecules a promising strategy for the development of novel anticancer therapeutics. The oncogenic p53 mutation Y220C, which accounts for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa9c94e4d5285fe5ab37566b73ee9eec
http://europepmc.org/articles/PMC5986712
http://europepmc.org/articles/PMC5986712
Autor:
Andrea Testa, C.J. Ellis, Ola Epemolu, Alessio Ciulli, A. Brien, Matthias G. J. Baud, Andrew C. Runcie, L.V. Beurden, V. Coulthard, Kwok-Ho Chan, Kevin D. Read, Michael Zengerle
Publikováno v:
Chemical Science
Allele-specific chemical genetics enables selective inhibition within families of highly-conserved proteins. The four BET (bromodomain & extra-terminal domain) proteins – BRD2, BRD3, BRD4 and BRDT bind acetylated chromatin via their bromodomains an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37b43c496d0b74ab8be99e35668e795c
https://doi.org/10.1039/c7sc02536j
https://doi.org/10.1039/c7sc02536j
Autor:
Rainer Wilcken, Frank M. Boeckler, Rhiannon N. Jones, Matthias R. Bauer, John Spencer, Alan R. Fersht, Matthias G. J. Baud, Andreas C. Joerger
Publikováno v:
ACS Chemical Biology
Many oncogenic mutants of the tumor suppressor p53 are conformationally unstable, including the frequently occurring Y220C mutant. We have previously developed several small-molecule stabilizers of this mutant. One of these molecules, PhiKan083, 1-(9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f288de0304f808c5be22b5966aa89624
https://doi.org/10.1021/acschembio.6b00315
https://doi.org/10.1021/acschembio.6b00315